Regulation of co-transcription factor CITED1 in mouse bone metabolism

Abstract

Abstract: Objective To study the regulation of CITED1 in the mice bone metabolism, including osteogenesis/osteoclast balance in vivo to provide a theoretical basis for the treatment of osteoporosis. Methods Bone phenotypes such as femur length, bone mass, bone cortex and bone cancellous thickness of KO mice were measured by micro CT. Hematological related parameters of bone metabolism were determined by ELISA. RT-qPCR was used to detect the expression of bone marker genes to explore the causes of bone metabolism changes after CITED1 gene knockout. Results The expression of CITED1 was low in KO mice, indicating a successful CITED1 knockout. Femoral length, bone mass, bone cortex and bone cancellous thickness were significantly higher in KO mice than those in WT mice. The concentration of type I procollagen peptide (P1NP), osteocalcin (OC) and bone alkaline phosphatase (BALP) in serum of KO mice was significantly higher than those of WT mice, while the concentration of tartaric acid phosphatase (TRAP) was significantly lower. The expression of OC and BALP in KO mice was significantly higher than that in WT mice(P＜0.001). At the same time the expression of TRAP in KO mice was signifi- cantly lower(P＜0.05). Conclusions CITED1 knockout can up-regulate the expression of OC and BALP, and down-regulate the expression of TRAP for promoting bone formation and inhibiting bone resorption.

Key words: co-transcription factor CITED1, osteoporosis, parathyroid hormone, bone metabolism

CLC Number:

R589.5

QIU Yi-yan, ZHENG Yu-cheng, GUO Wei-zhuang, ZHOU Wen-yu, YAN Bin, YANG Xin-jian. Regulation of co-transcription factor CITED1 in mouse bone metabolism[J]. Basic & Clinical Medicine, 2020, 40(3): 294-298.

References

[1]Karlsson L, Mesterton J, Tepie MF, et al. Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control[J]. Arch Osteoporos, 2017,12:81-83. doi: 10.1007/s11657-017-0375-7.
[2]Boschitsch EP, Durchschlag E, Dimai HP. Age-related prevalence of osteoporosis and fragility fractures: real-world data from an Austrian Menopause and Osteoporosis Clinic[J]. Climacteric, 2017,20:157-163.doi: 10.1080/13697137.2017.1282452.
[3]Sun Y, Guo HH, Guo DD, et al. Divergence of genes encoding CITED1 and CITED2 in blunt snout bream (megalobrama amblycephala) and their transcriptional responses to hypoxia[J]. Front Physiol, 2018,9:186-188.doi: 10.3389/fphys.2018.00186.
[4]Li X, Chen X, Zhou W, et al. Effect of melatonin on neuronal differentiation requires CBP/p300-mediated acetylation of histone H3 lysine 14[J]. Neuroscience, 2017,364:45-59.doi: 10.1016/j.neuroscience.2017.07.064.
[5]Sauer M, Schuldner M, Hoffmann N, et al. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells[J]. Oncogene, 2017,36:933-941. doi: 10.1038/onc.2016.259.
[6]Ichise T, Yoshida N, Ichise H. CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signalling-induced tumour formation in mice[J]. J Pathol, 2019,249:39-51.doi: 10.1002/path.5279.
[7]Olzscha H, Fedorov O, Kessler BM, et al. CBP/p300 bromodomains regulate amyloid-like protein aggregation upon aberrant lysine acetylation[J]. Cell Chem Biol, 2017,24:9-23.doi: 10.1016/j.chembiol.2016.11.009.
[8]Castillo J, Wu E, Lowe C, et al. CBP/p300 drives the differentiation of regulatory T cells through transcriptional and non-transcriptional mechanisms[J]. Cancer Res, 2019,79:3916-3927. doi: 10.1158/0008-5472.CAN-18-3622.
[9]Xia E, Wang Y, Bhandari A, et al. CITED1 gene promotes proliferation, migration and invasion in papillary thyroid cancer[J]. Oncol Lett, 2018,16:105-112. doi: 10.3892/ol.2018.8653.
[10]Li H, Guan H, Guo Y, et al. CITED1 promotes proliferation of papillary thyroid cancer cells via the regulation of p21 and p27[J]. Cell Biosci,2018,8:57-60. doi: 10.1186/s13578-018-0256-9.
[11]Namwanje M, Liu L, Chan M, et al. The depot-specific and essential roles of CBP/p300 in regulating adipose plasticity[J]. J Endocrinol,2019,240:257-269. doi: 10.1530/JOE-18-0361.
[12]Xu B, Li Q, Chen N, et al. The LIM protein ajuba recruits DBC1 and CBP/p300 to acetylate ERalpha and enhances ERalpha target gene expression in breast cancer cells[J]. Nucleic Acids Res, 2019,47:2322-2335.doi: 10.1093/nar/gky1306.
[13]Howlin J, Cirenajwis H, Lettiero B, et al. Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours[J]. Peer J, 2015,3:e788.doi: 10.7717/peerj.788.
[14]Xu Y, Luo X, Fang Z, et al. Transcription coactivator Cited1 acts as an inducer of trophoblast-like state from mouse embryonic stem cells through the activation of BMP signaling[J]. Cell Death Dis, 2018,9:924-927. doi: 10.1038/s41419-018-0991-1.
[15]Ono M, Lai KKY, Wu K, et al. Nuclear receptor/Wnt beta-catenin interactions are regulated via differential CBP/p300 coactivator usage[J]. PLoS One, 2018,13:e0200714.doi: 10.1371/journal.pone.0200714.